Johnson & Johnson, Takeda, Chong Kun Dang and Handok were among the participants in a series B round expected to advance acne and IBD drugs into the clinic.
Israel-based drug developer BiomX secured $32m on Wednesday in a series B round co-led by Johnson & Johnson Innovation – JJDC and Takeda Ventures, subsidiaries of pharmaceutical firms Johnson & Johnson and Takeda.
SBI Japan-Israel Innovation Fund, a vehicle backed by financial services provider SBI Group, also co-led the round, along with financial services group Mirae Asset, healthcare investment firm OrbiMed and VC firms Seventure Partners and 8VC.
The round included pharmaceutical companies Chong Kun Dang and Handok, Consensus Business…
